Leukemia, Lymphoblastic, Mercaptopurine Adverse Reaction
Conditions
Keywords
Mercaptopurine, acute lymphoblastic leukemia, hematotoxicity
Brief summary
Subjects who are recruited in this study are LLA patient, who are treated for routine control to Cipto Mangunkusumo Hospital, who meet the inclusion criteria and do not meet the exclusion criteria.
Detailed description
On the day of the control patient, (usually the patient is asked for routine control at week 3 on mercaptopurin) routine blood tests are performed. Patients and parents were given an explanation of this study. If patients and parents are willing to take part in the study, they are asked to sign informed consent. Patients who meet the inclusion criteria and do not meet the exclusion criteria, are recorded for demographic data and 5 ml of blood taking. The blood is directly divided into three, 2 mL for hematologic examination and albumin level, 1 mL for genotyping, and 2 mL for examination of drug levels. Routine hematologic examination and albumin levels were performed in the Cipto Mangunkusumo hospital laboratory. For genotypic examination, blood samples were stored at -80C, until they were used for analysis. For examination of the drug levels the blood sample is centrifuged and the erythrocyte preparation is then stored at -80C, until it is used for analysis.
Interventions
None listed
Sponsors
Indonesia University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Acute lymphoblastic leukemia (ALL) patients, 1 until 18 years old, male or female, who come to Cipto Mangunkusumo Hospital, Jakarta, Indonesia * Received 6MP chemotherapy at least 1 month maintenance phase * Received maintenance phase treatment regimen * Willing to participate in research, signed informed consent and obtained parental consent to participate in research
Exclusion criteria
* Patients are experiencing severe infections * Patients receiving colony stimulating factor (CSF), allopurinol, mesalazine, olsalazine, and sulfasalazine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia, the relationship the event with genotyping and phenotyping | August 2017 - May 2018 | Haematology data (hemoglobin, leukocites, platelets, absolute neutrophil count), TPMT genotyping, and blood concentration of 6-meMP and 6-TGN (=phenotyping). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| other Factors that can influence the incidence of hematotoxicity | July 2017 - May 2018 | relaps risk stratification (High risk or standard risk), nutrition status,and albumin levels |
Countries
Indonesia
Outcome results
None listed